Age at diagnosis |
Median age 66 years (IQR 56–73 years) |
<50 years |
61 (11.3%) |
50–70 years |
296 (54.9%) |
>70 years |
182 (33.8%) |
Body mass index (BMI, kg/m2) |
Median BMI 32 kg/m2 (IQR 26–39 kg/m2) |
Underweight |
6 (1.1%) |
Normal weight |
83 (15.4%) |
Overweight |
128 (23.8%) |
Obese |
322 (59.7%) |
Grade of endometrial cancer |
1 |
243 (45.1%) |
2 |
122 (22.6%) |
3 |
174 (32.3%) |
Stage of endometrial cancer |
I |
403 (74.9%) |
II |
56 (10.4%) |
III |
71 (13.0%) |
IV |
9 (1.7%) |
Histology |
Endometrioid |
404 (75.0%) |
Non‐endometrioid |
135 (25.0%) |
Bohkman’s category |
Type 1 |
364 (67.5%) |
Type 2 |
175 (32.5%) |
Lymphovascular invasion (n = 536) |
No |
382 (71.3%) |
Yes |
154 (28.7%) |
Depth of myometrial invasion |
<50% |
346 (64.2%) |
≥50% |
193 (35.8%) |
Social deprivation group (n = 532) |
Social group I (least deprived) |
147 (27.6%) |
Social group II (middle group) |
186 (35.0%) |
Social group III (most deprived) |
199 (37.4%) |
History of diabetes mellitus (n = 535) |
Yes |
108 (20.2%) |
No |
427 (79.8%) |
Primary treatment |
Surgery |
473 (87.8%) |
Hormonal (fertility‐sparing reasons) |
23 (4.3%) |
Hormonal (not fit for surgery) |
40 (7.4%) |
Radiotherapy |
3 (0.6%) |
Adjuvant treatment |
Yes |
240 (44.5%) |
No |
299 (55.5%) |
Recurrence |
Yes |
78 (14.5%) |
No |
460 (85.5%) |
Survival status at end of follow‐up |
Alive |
429 (79.6%) |
Cancer‐specific mortality |
76 (14.1%) |
Non‐cancer related mortality |
34 (6.3%) |
Total |
539 (100%) |